Gynecologic Cancer

This analysis of the KEYNOTE-826 trial focused on health-related quality of life in patients with persistent, recurrent or metastatic cervical cancer.

Social media, including Facebook groups, can help connect patients with rare cancers like granulosa cell tumors to researchers, allowing them to learn more about disease management.

Interim findings from a clinical trial showed that adding Lynparza and Imfinzi to an Avastin and chemotherapy regimen tended to improve the time patients lived before their disease got worse.

Cryocompression was found to be tolerable and effective in preventing chemotherapy-induced peripheral neuropathy in a small study.

The Food and Drug Administration approved Keytruda for adult and pediatric patients with previously treated unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.

The way I see it, double the cancer diagnoses means double the victory.

The phase 2 DESTINY-PanTumor02 trial included patients with HER2-expressing solid tumors such as bladder, pancreatic and rare tumors.

The first patient has been enrolled in a clinical trial evaluating IMNN-001, an immunotherapy, combined with Avastin for the treatment of advanced ovarian cancer.

On multiple occasions, doctors told me not to worry, but I ended up being diagnosed with a rare cancer called leiomyosarcoma.

Sometimes the steps I take leaving the hospital make me feel like I’m flying if I received good news, but other times, I’m walking quickly to my car before I begin to cry.

The hold has been placed due to visual side effects in a number of patients with solid tumors.

The FDA granted a regular approval to patients with recurrent or advanced dMMR endometrial cancer.

Postmenopausal women cancer survivors, including lung, breast, colorectal and endometrial cancer, may have a greater physical function decline than is generally expected at their age, which may lead to lower quality of life after treatment.

When I started cancer treatment, I had been cast in some sci-fi flick without prior consent.

Findings from the phase 3 NRG-GY018 trial found that the addition of Keytruda to standard chemotherapy improved progression-free survival in patients with stage 3 to 4 or recurrent endometrial cancer.

Chemoradiotherapy may be an appropriate treatment option after surgery for patients with stage 3 endometrial cancer, especially those are a higher risk of recurrence.

From Tennis star Chris Evert’s cancer-free status to Duran Duran’s Andy Taylor talking about his prostate cancer, here’s what’s happening in the oncology space this week.

Patients undergoing surgery for gynecologic cancer may benefit from acupressure, acupuncture and other relaxation techniques regarding pain relief and a reduction in anxiety.

Women who were taking beta-blockers, a medicine to treat heart conditions like high blood pressure, among others, near the time of surgery for epithelial ovarian cancer may confer a survival benefit years after undergoing a procedure.

Investigators have administered Keytruda and ONC-392 the first patients with platinum resistant ovarian cancer.

In 2023, instead of looking over my shoulder to see how cancer has invaded every aspect of my life, I’m vowing to face forward. No fear. No uncertainty. No what-ifs.

A novel three-drug combination bested standard-of-care regimens for patients with human papillomavirus-related cancers, according to phase 2 study results.

This is the only first-line trial to show benefit with immuno-oncology plus chemotherapy in patients with advanced or recurrent endometrial cancer.

In my cousin Barbara’s salon, a group of fellow Black women helped boost my confidence as I shaved my head after being diagnosed with cancer.

After being diagnosed with cancer, an amazing posse of loved ones formed around me, but perhaps nobody was as helpful as my loving husband.

From a uterine cancer survivor camping out in front of a store to meet the Astros’ Jose Altuve to Michael Armand Hammer’s death from cancer, here’s what’s happening in the cancer space this week.

One expert said that the FDA approval of the antibody-drug conjugate Elahere represents a new treatment option for patients with folate receptor alpha-positive, platinum resistant ovarian cancer.

The FDA approved Elahere for patients with pretreated, folate receptor alpha (FRα)-positive platinum-resistant gynecological cancers

I have many things to be thankful for regarding my ovarian cancer: from my recent CT scan results to an excellent oncology team.

The thought of hosting family for a week in the middle of cancer treatment made me anxious, so I set a boundary — and felt much better after the fact.